The Albany Gazette - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Albany - 02.04. 2025 - 09:45:42

NYSE - LSE

RBGPF	100%	68	$
RYCEF	3.48%	10.05	$
CMSC	0.18%	22.44	$
GSK	-2.3%	37.87	$
SCS	3.18%	11.32	$
RIO	0.25%	60.23	$
VOD	-1.08%	9.27	$
BCC	0.83%	98.91	$
NGG	0.26%	65.78	$
BTI	-0.66%	41.1	$
RELX	0.51%	50.67	$
AZN	-1.24%	72.6	$
BCE	-0.79%	22.78	$
CMSD	0.04%	22.82	$
BP	0.06%	33.81	$
JRI	0.31%	12.98	$

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

TECHNOLOGY 27.02.2025

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. 

Text size:

Details for the presentation are as follows:  

Abstract Number:  123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter:  Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time:  Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT

For more information, please visit the conference website here. 

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

(B.Smith--TAG)

Featured

AstraBit Welcomes John Buckley as Strategic Advisor to Drive Next Phase of Growth

NEW YORK CITY, NEW YORK / ACCESS Newswire / April 2, 2025 / AstraBit, a leading platform for automated and algorithmic crypto trading, announces the appointment of John Buckley to its Strategic Advisory Board. Buckley brings nearly three decades of experience in global financial markets, including expertise in trading infrastructure, exchange operations, and risk management. His appointment marks a significant milestone as AstraBit prepares for its next phase of institutional expansion and product innovation.

Vallor Raises $4M in Oversubscribed Seed Round to Put Contracts on Autopilot Saving Enterprise Procurement Teams Time and Money

Vallor's AI agents manage contracts autonomously-unlocking hidden insights, automating obligations, and eliminating admin work.

SKY+ and DGO Consolidate the Premium Experience for Their Users With AI From Mediagenix and Spideo to Offer Personalized Content and Live TV Recommendations

DIRECTV Latin America and SKY Brasil's streaming platforms have incorporated innovative technological solutions to enhance the curation of their extensive content portfolio, including a catalog of 15,000 titles and more than 400 live television channels.

Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City

LAS VEGAS, NV / ACCESS Newswire / April 2, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc. ("Ainnova"), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova will be a sponsor and its CEO, Vinicio Vargas, will be a featured speaker at the 2025 Healthcare Innovation Summit in Mexico City, Mexico.